AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9663361 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol
Number of subjects: 311
Study 9663361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 311
Study 8787252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 270
Study 8787252 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 270
Study 8787252 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 270
Study 2679368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 43
Study 2679368 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides (tobramycin and amikacin)
Number of subjects: 43
Study 959332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator and bronchial drainage
Number of subjects: 20
Study 959332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator/mucolytic agents and bronchial drainage
Number of subjects: 20
Study 959332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucolytic agent with bronchial drainage
Number of subjects: 20
Study 959332 — intervention group
Group type: COMPARATOR
Intervention: Comparison among three treatments
Number of subjects: 20
Study 31002537 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2017 (adalimumab biosimilar) 40 mg subcutaneous injection
Number of subjects: 197
Study 28445290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh + TrP-DN
Number of subjects: 44
Study 28445290 — intervention group
Group type: COMPARATOR
Intervention: Rh
Number of subjects: 44
Study 25406528 — intervention group
Group type: COMPARATOR
Intervention: 0 mg kg‐1 day‐1 (placebo)
Number of subjects: 285
Study 25406528 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg‐1 day‐1
Number of subjects: 285
Study 25406528 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg kg‐1 day‐1
Number of subjects: 285
Study 23004236 — intervention group
Group type: EXPERIMENTAL
Intervention: All fit SSO implants
Number of subjects: 25
Study 23004236 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI contact implants
Number of subjects: 25
Study 23004236 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI element implants
Number of subjects: 25
Study 21646579 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management (DCM)
Number of subjects: 396
Study 21646579 — intervention group
Group type: COMPARATOR
Intervention: Control (college-educated group)
Number of subjects: 396
Study 19672180 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (BIS 50-60)
Number of subjects: 128
Study 19672180 — intervention group
Group type: COMPARATOR
Intervention: Standard practice group (BIS recorded but not guiding drug administration)
Number of subjects: 128
Study 16965241 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micromol of glucosinolate (cohort A)
Number of subjects: 12
Study 16965241 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micromol of glucosinolate (cohort B)
Number of subjects: 12
Study 16965241 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micromol of isothiocyanate (cohort C)
Number of subjects: 12
Study 16965241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study 15093842 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph group
Number of subjects: 0
Study 15093842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabulation group
Number of subjects: 0
Study 15093842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10735015 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment comparable to white women
Number of subjects: 0
Study 10735015 — intervention group
Group type: COMPARATOR
Intervention: Stage of disease at diagnosis
Number of subjects: 0
Study 10735015 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional factors considered
Number of subjects: 0
Study 10735015 — intervention group
Group type: COMPARATOR
Intervention: Clinical and pathologic disease characteristics
Number of subjects: 0
Study 9311629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir with fluconazole (400 mg on day 1, 200 mg every day on days 2-5)
Number of subjects: 8
Study 9311629 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir alone (200 mg every 6 hr for 4 days)
Number of subjects: 8
Study 8349326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt intake (20 mmol sodium/d)
Number of subjects: 163
Study 8349326 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt intake (300 mmol sodium/d)
Number of subjects: 163
Study 8349326 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction
Number of subjects: 163
Study 3089521 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with informed consent
Number of subjects: 56
Study 3089521 — intervention group
Group type: COMPARATOR
Intervention: Placebo without informed consent (Control)
Number of subjects: 56
Study 30129411 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Study 201 and Bapineuzumab IV in OLE (placebo/bapi)
Number of subjects: 194
Study 30129411 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab (SC) or placebo SC in OLE
Number of subjects: 194
Study 30129411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (IV) in OLE
Number of subjects: 194
Study 27735787 — intervention group
Group type: EXPERIMENTAL
Intervention: Close contact casting (CCC)
Number of subjects: 620
Study 27735787 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 620
Study 24162762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular hyaluronic acid injections (2 cycles of 5 weekly injections at 6-month intervals) after high tibial osteotomy (HTO)
Number of subjects: 40
Study 24162762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intra‐articular injections after HTO)
Number of subjects: 40
Study 24162762 — intervention group
Group type: COMPARATOR
Intervention: Both groups (study and control)
Number of subjects: 40
Study 24162762 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (intra‐articular hyaluronic acid injections)
Number of subjects: 40
Study 22430450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control with insulin (target BGC 4‐6 mmol/L)
Number of subjects: 88
Study 22430450 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (restrictive guidelines for starting insulin, target BGC 8‐10 mmol/L)
Number of subjects: 88
Study 20649975 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen therapy
Number of subjects: 912
Study 20649975 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 912
Study 18847581 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper/low-density polyethylene nanocomposite IUD
Number of subjects: 100
Study 18847581 — intervention group
Group type: COMPARATOR
Intervention: Copper T220C IUD
Number of subjects: 100
Study 15753416 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain-specific cognitive abilities
Number of subjects: 168
Study 15753416 — intervention group
Group type: COMPARATOR
Intervention: Cognitive predictors added to standard medical model
Number of subjects: 168
Study 15753416 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairments in abstract reasoning and executive functioning
Number of subjects: 168
Study 15753416 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattention and perceptual disorders
Number of subjects: 168
Study 11954868 — intervention group
Group type: COMPARATOR
Intervention: IFNbeta‐1 b alone
Number of subjects: 161
Study 11954868 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1 b combined with monthly intravenous methylprednisolone (MP)
Number of subjects: 161
Study 11954868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFNbeta‐1 b + MP)
Number of subjects: 161
Study 10375338 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogesterone, 2.5 mg/d
Number of subjects: 128
Study 10375338 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 128
Study 7731281 — intervention group
Group type: EXPERIMENTAL
Intervention: Female physicians
Number of subjects: 250
Study 7731281 — intervention group
Group type: COMPARATOR
Intervention: Male physicians
Number of subjects: 250
Study 1974678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol aerosol (400 micrograms qid)
Number of subjects: 36
Study 1974678 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol aerosol (400 micrograms qid)
Number of subjects: 36
Study 1974678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol aerosol
Number of subjects: 36
Study 1974678 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol aerosol
Number of subjects: 36
Study 6775954 — intervention group
Group type: COMPARATOR
Intervention: 500 mg chenodeoxycholic acid (4 X 125 mg gelatin‐coated capsules)
Number of subjects: 9
Study 6775954 — intervention group
Group type: COMPARATOR
Intervention: 250 mg chenodeoxycholic acid
Number of subjects: 9
Study 6775954 — intervention group
Group type: COMPARATOR
Intervention: 500 mg chenodeoxycholic acid
Number of subjects: 9
Study 6775954 — intervention group
Group type: COMPARATOR
Intervention: 750 mg chenodeoxycholic acid
Number of subjects: 9
Study 30307514 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cut-off dialyzers (with extended middle molecule removal) during hemodialysis
Number of subjects: 35
Study 30307514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzers during hemodialysis and hemodiafiltration
Number of subjects: 35
Study 27992251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group
Number of subjects: 32
Study 27992251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance group
Number of subjects: 32
Study 27992251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 26087610 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night
Number of subjects: 0
Study 26087610 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 23351813 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial oral treatment with antibiotics after a minimum of 10 days of parenteral treatment.
Number of subjects: 400
Study 23351813 — intervention group
Group type: COMPARATOR
Intervention: Full parenteral treatment (unchanged parenteral therapy).
Number of subjects: 400
Study 21310875 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus hydrocodone
Number of subjects: 300
Study 21310875 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 300
Study 19571779 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (LA+TCI)
Number of subjects: 100
Study 19571779 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid Anesthesia (SA)
Number of subjects: 100
Study 17593859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 microg/kg) plus IV PCA morphine
Number of subjects: 33
Study 17593859 — intervention group
Group type: COMPARATOR
Intervention: IV PCA morphine alone
Number of subjects: 33
Study 15220231 — intervention group
Group type: COMPARATOR
Intervention: INS + MET (dual therapy)
Number of subjects: 28
Study 15220231 — intervention group
Group type: COMPARATOR
Intervention: INS + TGZ (dual therapy)
Number of subjects: 28
Study 15220231 — intervention group
Group type: EXPERIMENTAL
Intervention: INS + MET, add TGZ (triple therapy)
Number of subjects: 28
Study 15220231 — intervention group
Group type: EXPERIMENTAL
Intervention: INS + TGZ, add MET (triple therapy)
Number of subjects: 28
Study 15220231 — intervention group
Group type: EXPERIMENTAL
Intervention: INS + TGZ add MET (triple therapy)
Number of subjects: 28
Study 15220231 — intervention group
Group type: EXPERIMENTAL
Intervention: INS + MET add TGZ (triple therapy)
Number of subjects: 28
Study 11216968 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2416
Study 11216968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2416
Study 9701277 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 10
Study 9701277 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg once daily
Number of subjects: 10
Study 8029514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and physiotherapy
Number of subjects: 8
Study 8029514 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 8
Study 2679483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive amitriptyline hydrochloride
Number of subjects: 58
Study 2679483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive desipramine hydrochloride
Number of subjects: 58
Study 2679483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 168120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (500 mg daily for 10 weeks)
Number of subjects: 66
Study 168120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (750 mg three times daily for 10 days)
Number of subjects: 66
Study 168120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 66
Study 168120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and Metronidazole
Number of subjects: 66
Study 31166383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (PV group) with 7 mL/kg tidal volume and personal level of PEEP
Number of subjects: 120
Study 31166383 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV group) with 10 mL/kg tidal volume without PEEP
Number of subjects: 120
Study 31166383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (PV group)
Number of subjects: 120
Study 31166383 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV group)
Number of subjects: 120
Study 28384682 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR-CBT
Number of subjects: 125
Study 28384682 — intervention group
Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 125
Study 25613384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) with 75% of maximum mandibular protrusion and 5 mm vertical opening
Number of subjects: 9
Study 25613384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) with 75% of maximum mandibular protrusion and 10 mm vertical opening
Number of subjects: 9
Study 25613384 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (no MAS)
Number of subjects: 9
Study 23204161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ART using CD4(+) T‐cell count as a guide
Number of subjects: 5295
Study 23204161 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART
Number of subjects: 5295
Study 23204161 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific ART medications (e.g., atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir, lopinavir/ritonavir)
Number of subjects: 5295
Study 23204161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 5295
Study 21421658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (200 mg, single oral dose)
Number of subjects: 100
Study 21421658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg, o.d.) and Vitamin C (150 mg, o.d.)
Number of subjects: 100
Study 21421658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18303459 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy (D)
Number of subjects: 84
Study 18303459 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic sequestrectomy (S)
Number of subjects: 84
Study 18303459 — intervention group
Group type: COMPARATOR
Intervention: Comparison of D and S
Number of subjects: 84
Study 15782521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-use cessation intervention delivered by trained dental practitioners
Number of subjects: 190
Study 15782521 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study 15782521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-use cessation intervention
Number of subjects: 190
Study 14535104 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based obesity intervention including health education activities
Number of subjects: 3600
Study 14535104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3600
Study 10919733 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 333
Study 8864324 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally applied prazosin
Number of subjects: 0
Study 8864324 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 1732771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor (amniotomy within one hour of diagnosis, oxytocin infusion starting at 6 mU/min, increasing to a maximum of 36 mU/min)
Number of subjects: 705
Study 1732771 — intervention group
Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 705
Study 1732771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 705
Study 6431939 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 0
Study 6431939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 6431939 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological treatment
Number of subjects: 0
Study 30897697 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise under normobaric normoxia (PIO₂ = 150 mmHg, FIO₂ = 0.21)
Number of subjects: 30
Study 30897697 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise under normobaric severe hypoxia (PIO₂ = 87 mmHg, FIO₂ = 0.12, simulated at an altitude of 4000 m)
Number of subjects: 30
Study 30897697 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and hypoxia
Number of subjects: 30
Study 30897697 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes of RT and SpO₂ under normoxia and hypoxia
Number of subjects: 30
Study 29781651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure (long)
Number of subjects: 88
Study 29781651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure (short)
Number of subjects: 88
Study 29781651 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 88
Study 29781651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 88
Study 26563527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2-stage laparoscopic orchiopexy with vascular division (not randomized)
Number of subjects: 80
Study 26563527 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy evaluation
Number of subjects: 80
Study 26563527 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic testes
Number of subjects: 80
Study 26563527 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed internal ring
Number of subjects: 80
Study 25418216 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation protection cabin
Number of subjects: 37
Study 25418216 — intervention group
Group type: COMPARATOR
Intervention: Standard extraction technique
Number of subjects: 37
Study 22154650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/actinomycin/vincristine-based chemotherapy with local therapy (radiotherapy or surgery)
Number of subjects: 97
Study 22154650 — intervention group
Group type: COMPARATOR
Intervention: No local therapy
Number of subjects: 97
Study 22154650 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy or brachytherapy
Number of subjects: 97
Study 22154650 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 97
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement
Number of subjects: 36
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II Low
Number of subjects: 36
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio Flow
Number of subjects: 36
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio
Number of subjects: 36
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 36
Study 20945750 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite
Number of subjects: 36
Study 18585498 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 106
Study 18585498 — intervention group
Group type: COMPARATOR
Intervention: Nonstatin
Number of subjects: 106
Study 15860951 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping method applied three times a week for four weeks (total of 12 sessions)
Number of subjects: 63
Study 15860951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taping method)
Number of subjects: 63
Study 12569115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria-fermented milk (BFM), 100 mL/day for one year
Number of subjects: 21
Study 12569115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BFM supplementation)
Number of subjects: 21
Study 12569115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria-fermented milk (BFM)
Number of subjects: 21
Study 10683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance with grey lights against a dark background
Number of subjects: 4
Study 10683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminance with equiluminant yellow lights
Number of subjects: 4
Study 10683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Left visual field presentation of lights
Number of subjects: 4
Study 10683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual field presentation of lights
Number of subjects: 4
Study 10683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Callosal agenesis subject
Number of subjects: 4
Study 9316009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (CBDCA) 400 mg/m2 on day 1 and oral etoposide 50 mg/m2 on days 1-21 (Group I)
Number of subjects: 120